Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy - 1 Oct 2003

Henderson Clare, Brancolini Claudio

Abstract excerpt

Histones are abundant proteins that coordinate the organization of eukaryotic nucleosomes. Post-translational modifications of histones-acetylation, phosphorylation and methylation-locally modulate the higher order nucleosome structure. Acetylation and deacetylation of histones occur at their N-t...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Drug Resistance, Neoplasm
Share to Gene Expression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone Deacetylase Inhibitors

Share to Histone Deacetylases

Share to Phenotype

Source

Identifiers

PMID: 14643295
DOI: 10.1016/s1368-7646(03)00067-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026. Prepared record publication-14643295-2026-09-01.1. Manifest publication-graph-cohort-2026-09-01.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype.PMID 14643295Read ↗

Histone-Deacetylase Inhibitors for the Treatment of CancerSemantic proximity Read ↗

Molecular Pathways: Old Drugs Define New Pathways: Non-Histone Acetylation at the Crossroads of the DNA Damage Response and AutophagySemantic proximity Read ↗

Histone Deacetylase Inhibitors in Cancer TherapySemantic proximity Read ↗

Histone deacetylase inhibitors in cancer therapy. A reviewSemantic proximity Read ↗

Reversible acetylation of chromatin: Implication in regulation of gene expression, disease and therapeuticsSemantic proximity Read ↗

Targeting Histone Deacetylases: Opportunities for Cancer Treatment and ChemopreventionSemantic proximity Read ↗

Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer.Semantic proximity Read ↗

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.Semantic proximity Read ↗

p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell DeathSemantic proximity Read ↗

Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53Semantic proximity Read ↗

Chromatin as an old and new anticancer targetSemantic proximity Read ↗

Dysregulation of histone deacetylases in carcinogenesis and tumor progression: a possible link to apoptosis and autophagySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.